Compare AGMB & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGMB | TECX |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | Belgium | United States |
| Employees | 62 | 60 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.4M | 554.1M |
| IPO Year | N/A | N/A |
| Metric | AGMB | TECX |
|---|---|---|
| Price | $11.45 | $29.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $32.00 | ★ $75.20 |
| AVG Volume (30 Days) | 64.9K | ★ 211.4K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.00 | $14.39 |
| 52 Week High | $17.45 | $35.99 |
| Indicator | AGMB | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 52.26 |
| Support Level | $9.62 | $27.39 |
| Resistance Level | $12.29 | $31.17 |
| Average True Range (ATR) | 0.93 | 1.82 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 36.97 | 66.98 |
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.